SCHEMBL25035392

SCHEMBL25035392

Cc1nc(NS(=O)(=O)Cc2ccc(F)cc2)ccc1-c1nc2cnc(N)nc2n(C(C)C)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 4/20 0.41
RORC P51449 3/20 0.39
CYP1A2 P05177 6/20 0.36
USP2 O75604 6/20 0.36
CYP3A4 P08684 5/20 0.36
CYP2C19 P33261 4/20 0.36
ALDH1A1 P00352 4/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
HSD17B10 Q99714 3/20 0.36
CLK4 Q9HAZ1 1/20 0.36
F2 P00734 2/20 0.36
CYP2C9 P11712 4/20 0.35
TSHR P16473 3/20 0.35
HIF1A Q16665 2/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
MTOR P42345 3/20 0.35
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25035691 0.86 ERN1 (0.47) ERN1RORCCYP1A2USP2CYP3A4
SCHEMBL25034224 0.85 RORC (0.38) ERN1RORCMTORBRAF
SCHEMBL22200825 0.85 CYP1A2 (0.36) RORCCYP1A2USP2CYP3A4CYP2C19
SCHEMBL25035463 0.84 ERN1 (0.42) ERN1RORCCYP1A2USP2CYP3A4
SCHEMBL25035335 0.83 ERN1 (0.58) ERN1CYP1A2USP2CYP3A4CYP2C19
SCHEMBL25034228 0.82 FEN1 (0.39) RORCMTOR
SCHEMBL25035661 0.82 ERN1 (0.48) ERN1RORCCYP1A2USP2CYP3A4
SCHEMBL25034187 0.82 ERN1 (0.43) ERN1RORCF2BRAF
SCHEMBL22200501 0.82 ERN1 (0.64) ERN1RORCCYP1A2USP2CYP3A4
SCHEMBL22191222 0.82 ERN1 (0.64) ERN1RORCCYP1A2USP2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE PARAZA PHARMA, INC. (CA) 2023-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE TYMP, TYMS, DPYD ERN1 3167/4885RORC 528/4885CYP1A2 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.